When was Ionpath founded?

Ionpath was founded in 2014 and raised its 1st funding round 3 years after it was founded.

Where is Ionpath located?

Ionpath is headquartered in Menlo Park, United States. It is registered at 960 O’Brien Dr Menlo Park, CA 94025.

Who is the current CEO of Ionpath?

Harris Fienberg and Paul Davy s of Ionpath.

How many employees does Ionpath have?

As of Apr 30, 2026, the latest employee count at Ionpath is 13.

Is Ionpath a funded company?

Ionpath is a funded company, having raised a total of $18M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Aug 20, 2017.

When was the latest funding round of Ionpath?

Ionpath's latest funding was a $***** Series B round on May 11, 2022, with participation from 1 investor. Its primary sector is Life Sciences Platforms and Tools. In United States, the Life Sciences Platforms and Tools sector has seen $633M in funding in 2026 to date.

Where does Ionpath rank among its competitors?

Ionpath ranks 9th amongst 177 active competitors, of which 48 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Lucida Medical, which secured $11.5M in Mar, 2026.

Who are the top competitors of Ionpath?

Ionpath's top competitors include Oxford Instruments, Scholar Rock and SpectraWAVE. Among them, Lucida Medical secured the most recent funding round in March, 2026.

Ionpath - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of an imaging platform for tissue biopsies. It has designed a mass spec-based imaging platform for tissue biopsy called multiplexed ion beam imaging. The platform allows higher resolution and more samples can be screened simultaneously than the optical microscope and other mass spec-based imaging systems. The technology has diverse applications and can be used in research as well as diagnostic sectors.

Website: ionpath.com
Social
Email ID: *****@ionpath.com
Registered Address: 960 O’Brien Dr Menlo Park, CA 94025

Key Metrics

Founded Year

2014

Location

Menlo Park, United States

Stage

Series B

Total Funding

$18M in 3 rounds

Latest Funding Round

Series B, May 11, 2022, $*****

Investors

Thermo Fisher Scientific & 9 more

Ranked

9^th among 177 active competitors

Employee Count

13 as on Apr 30, 2026

Similar Companies

Oxford Instruments & 183 more

View Ionpath's full profile

Ionpath is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Ionpath, Inc CIN: 47-1861335 , United States, Active	Dec 31, 2013	-	37 (As on Dec 31, 2020)	-
Ionpath, Inc. CIN: 001t000000WoM9GAAV , United States, Active	Nov 16, 2018	-	-	-

Ionpath has raised a total funding of $18M over 3 rounds. Its first funding round was on Aug 20, 2017. Its latest funding round was a Series B round on May 11, 2022 for $*****. 1 investor participated in its latest round. Ionpath has 10 institutional investors.

Here is the list of recent funding rounds of Ionpath:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 11, 2022	4766731	Series B	4863853	9117305	1139745	7196628
Sep 24, 2020	6473911	Series B	4124595	2330673	8130157	Bruker & 4 more
Aug 20, 2017	2976504	Seed	7086296	5592155	Agile Angel	1716197

Access funding benchmarks and valuations. Sign up today!

View details of Ionpath's funding rounds and investors

The founders of Ionpath are Sean Bendall, Garry Nolan and Harris Fienberg. Paul Davy is the CEO of Ionpath.

Here are the details of Ionpath's key team members:

Sean Bendall: Former Co-Founder of Ionpath.
Garry Nolan: Former Co-Founder of Ionpath.
Contact Info: 1 email address
Harris Fienberg: Co-Founder and CEO of Ionpath.
Paul Davy: CEO of Ionpath.

View details of Ionpath's Founder profiles and Board Members

Ionpath's employee count trend

Ionpath has 13 employees as of Apr 26. Here is Ionpath's employee count trend over the years:

Uncover Ionpath's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Ionpath include Oxford Instruments, Scholar Rock and SpectraWAVE. Here is the list of Top 10 competitors of Ionpath, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Oxford Instruments 1959, High Wycombe (United Kingdom), Public	Manufacturer of scientific technology for atomic and molecular level research	-	Europa	70/100
2nd	Scholar Rock 2012, Cambridge (United States), Public	Developer of Antibody-based drugs for the treatment of primary myopathies	$103M	Fidelity Investments, Invus & 9 others	61/100
3rd	SpectraWAVE 2012, Waltham (United States), Acquired	Provider of diagnostic photonic imaging	$79.9M	Deerfield, Johnson & Johnson Innovation – JJDC ... & 6 others	60/100
4th	Leica Microsystems 1914, Wetzlar (Germany), Acquired	Manufacturer of microscopes, microscope software, cameras, parts, and accessories	-	SV Health Investors, Westlake Ventures & 1 others	59/100
5th	SamanTree Medical 2014, Lausanne (Switzerland), Series C	Developer of digital microscopy system for high-resolution imaging of tissue	$57.5M	Panakes Partners, European Investment Bank ... & 12 others	58/100
6th	Lucida Medical 2019, Cambridge (United Kingdom), Series A	Developer of MRI-based cancer screening technology using artificial intelligence (AI)	$11.5M	prostate-cancer-research.org.uk, XTX Markets ... & 19 others	58/100
7th	Sysmex 1968, Kobe (Japan), Public	Developer of diagnostic instruments, reagents, and related software	-	-	54/100
8th	Perfint Healthcare 2005, Chennai (India), Series D	Developer of solutions for image-guided interventional procedures	$41.5M	Norwest, Chiratae Ventures & 7 others	54/100
9th	Ionpath 2014, Menlo Park (United States), Series B	Developer of an imaging platform for tissue biopsies	$18M	Samsara BioCapital, ND Capital & 8 others	53/100
10th	RAYDIAX 2021, Magdeburg (Germany), Series A	Developer of therapy-assist CT system for minimally invasive interventions	$8.4M	Bmp Ventures, HTGF & 4 others	52/100